Partnership between Camgenium and Cardiac Tech for enhancing post-cardiac surgery outcomes utilizing Pace-Protect technology
New Medical Device for Open-Heart Surgery Patients Set for Clinical Trials
A groundbreaking medical device named Pace-Protect, developed by Camgenium and Cardiac Tech, is set to undergo clinical trials. This innovative device is designed to monitor all aspects of temporary pacing and report acute changes immediately to clinicians via a cloud-based platform and app.
The collaboration between Camgenium, a leading medical software engineering company, and Cardiac Tech has resulted in the development of Pace-Protect. The device is intended to minimize adverse events related to temporary pacemakers, which are reported to cause approximately 1,500 serious adverse events (SAEs) annually in the US alone due to their management following open-heart surgery.
Pace-Protect allows real-time patient electrogram (EGM) data to be transmitted to the clinical team at high data rates in emergencies, potentially preventing these SAEs. The device's functioning is made possible by Camgenium's proprietary Soft Silicon medical device grade two-way device communications technology for data transmission.
Soft Silicon establishes world-class data security for patient confidentiality and high resilience to ensure individual Pace-Protects never lose contact with the cloud. The Pace-Protect prototype also includes a cloud-based platform and app for real-time monitoring and alerts.
The Pace-Protect prototype has been developed to ISO 13485 and IEC 62304 Class IIa standards, ensuring the highest level of quality and safety. While specific details on Pace-Protect’s design, function, and clinical impact are not yet available, it is clear that the device is set to revolutionize the management of temporary pacemakers following open-heart surgery.
For more information about Pace-Protect and its potential impact on patient outcomes, further manufacturer information or clinical studies will be necessary.
[1] Mayo Clinic. (2021). Pacemaker. Retrieved from https://www.mayoclinic.org/tests-procedures/pacemaker/about/pac-20384522
[2] American Heart Association. (2021). Cardiac Resynchronization Therapy. Retrieved from https://www.heart.org/en/health-topics/heart-failure/treatment-options-for-heart-failure/cardiac-resynchronization-therapy
[4] National Heart, Lung, and Blood Institute. (2021). What is a pacemaker? Retrieved from https://www.nhlbi.nih.gov/health-topics/what-pacemaker
- The new medical device, Pace-Protect, is set to revolutionize digital health by monitoring and reporting acute changes in temporary pacing during clinical trials, with the aim of reducing serious adverse events related to temporary pacemakers following open-heart surgery.
- The development of Pace-Protect is a collaboration between Camgenium, a leader in medical software engineering, and Cardiac Tech, harnessing science and technology to advance health-and-wellness, specifically cardiovascular health, by minimizing adverse events related to temporary pacemakers.
- The Pace-Protect prototype, built using Camgenium's proprietary Soft Silicon medical device grade two-way device communications technology, ensures world-class data security for patient confidentiality and high resilience, making it possible for the real-time transmission of patient electrogram data to the clinical team in emergencies.
